PERSONENI, NICOLA
 Distribuzione geografica
Continente #
EU - Europa 1.589
NA - Nord America 1.371
AS - Asia 390
OC - Oceania 8
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 3
AF - Africa 2
Totale 3.367
Nazione #
US - Stati Uniti d'America 1.353
GB - Regno Unito 659
DE - Germania 309
SE - Svezia 271
CN - Cina 217
IT - Italia 120
IE - Irlanda 68
FR - Francia 53
SG - Singapore 47
IN - India 37
FI - Finlandia 29
KR - Corea 24
UA - Ucraina 23
JP - Giappone 18
CA - Canada 16
VN - Vietnam 14
NL - Olanda 10
BE - Belgio 9
HK - Hong Kong 9
TR - Turchia 9
AU - Australia 7
GR - Grecia 7
RU - Federazione Russa 6
RO - Romania 5
DK - Danimarca 4
ES - Italia 4
TW - Taiwan 4
CH - Svizzera 3
EU - Europa 2
IL - Israele 2
MY - Malesia 2
NO - Norvegia 2
PT - Portogallo 2
TH - Thailandia 2
AN - Antille olandesi 1
AP - ???statistics.table.value.countryCode.AP??? 1
AT - Austria 1
BA - Bosnia-Erzegovina 1
BR - Brasile 1
CL - Cile 1
CO - Colombia 1
EC - Ecuador 1
EG - Egitto 1
HU - Ungheria 1
IM - Isola di Man 1
IR - Iran 1
JM - Giamaica 1
KH - Cambogia 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PK - Pakistan 1
TN - Tunisia 1
UZ - Uzbekistan 1
Totale 3.367
Città #
Southend 616
Chandler 211
Frankfurt am Main 210
Fairfield 155
Seattle 137
Wilmington 100
Princeton 81
Ashburn 75
Woodbridge 72
Dublin 68
Houston 63
Milan 54
Ann Arbor 46
Beijing 44
Cambridge 42
Nanjing 40
Andover 30
Des Moines 29
Dearborn 25
Bengaluru 22
New York 20
Shanghai 18
Singapore 18
Phoenix 16
Redwood City 15
Eitensheim 11
San Diego 11
Shenyang 11
Bitonto 10
Toronto 10
Changsha 8
Mountain View 8
Silver Spring 8
Boardman 7
Brussels 7
Guangzhou 7
Hebei 6
Jinan 6
Nanchang 6
Tianjin 6
Chicago 5
Helsinki 5
Jiaxing 5
Kunming 5
Seoul 5
Tokyo 5
Berlin 4
Hefei 4
Ningbo 4
Dallas 3
Grafing 3
Mumbai 3
Munich 3
Redmond 3
Taipei 3
Zhengzhou 3
Bucheon 2
Buffalo 2
Chene-Bourg 2
Cranford 2
Dossenheim 2
Fuzhou 2
Gallo 2
Groningen 2
Haikou 2
Hangzhou 2
Himeji 2
Hong Kong 2
Kent 2
Khon Kaen 2
Kuala Lumpur 2
Leiden 2
Madrid 2
Osaka 2
Sartrouville 2
Stavanger 2
Trabzon 2
Wuhan 2
Allen 1
Bethesda 1
Birmingham 1
Bogotá 1
Borås 1
Boston 1
Bucharest 1
Budapest 1
Burlington 1
Bühl 1
Carlsbad 1
Central 1
Central District 1
Chengdu 1
Chongqing 1
Ciampino 1
Clearwater 1
Cleveland 1
Corciano 1
Darmstadt 1
Douglas 1
Falkenstein 1
Totale 2.458
Nome #
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 170
Fatal Infusion Reaction to Cetuximab : The Need for Predictive Risk Factors and Safer Patient Selection 160
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 157
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 152
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. 145
KRAS mutation in lung metastases from colorectal cancer : Prognostic implications 140
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer : a safe and effective approach 128
Epidermal growth factor receptor gene copy number in esophageal cancer and outcome prediction to gefitinib : does intratumoral heterogeneity matter? 128
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 127
Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma 117
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. 112
Hepatocellular Carcinoma : A Global Disease in Need of Individualized Treatment Strategies 111
A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma 110
Achievements in systhemic therapies in the pre-genomic era in metastatic breast cancer 110
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 103
Standardisation of EGFR FISH in colorectal cancer: Results of an international interlaboratory reproducibility ring study 100
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer : the VanGogh study 99
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression : a Phase II Study 96
Diagnostic accuracy of 11C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 94
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma 91
Outcome prediction to erlotinib in gastroesophageal adenocarcinomas : can we improve epidermal growth factor receptor and phospho-AKT testing? 89
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 88
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 84
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study 75
Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery : a retrospective study 74
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy 66
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 64
Tivantinib : a new promising mesenchymal–epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 62
Biomarkers in hepatocellular carcinoma - Letter 61
HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma 60
Hepatic intra-arterial injection of Yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipes 59
Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity 57
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer 53
Tivantinib for second-line treatment of advanced hepatocellular carcinoma : a randomised, placebo-controlled phase 2 study 51
Reply to Y. Pointreau et al 48
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab 45
Tivantinib for hepatocellular carcinoma 44
Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells 44
Response prediction to EGFR-targeted therapies in colorectal cancer 38
Sorafenib in Hepatitis C Virus-Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater! 30
null 3
Totale 3.645
Categoria #
all - tutte 9.313
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.313


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201975 0 0 0 0 0 0 0 0 0 0 45 30
2019/2020543 57 13 18 73 41 74 54 55 72 54 15 17
2020/2021434 42 21 59 13 45 24 13 35 24 34 62 62
2021/2022482 56 39 8 46 19 49 43 17 29 39 44 93
2022/2023619 91 105 74 72 48 109 3 35 37 14 25 6
2023/2024413 12 18 14 30 75 17 53 46 21 57 70 0
Totale 3.645